Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Bayer	50419039501	Nubeqa® (darolutamide) 300 mg tablet	2019-08-05	11550.0000	None	1	200	None	1	2014-06-02	68000000.0000	None	Entered into agreement with Orion to co-develop on 6/2/2014 for $68 million upfront. Baye rwill commercialize in the US and pay $45 million at first US sale and ongoing royalties not publicly disclosed.	None	None
Baxter Healthcare Corporation	00338955810	EPTIFIBATIDE	2019-02-21	240.0000	None	1	None	None	None	None	None	None	Not aquired	This is the seventh Eptifibatide on the market in the US. The first is a flexible IV container. Marketing pricing plan and estimated patient numbers are not publicly available or in the public domain and are therefore being kept confidential.	None
Baxter Healthcare Corporation	00338006301	Doxil 20mg-10ml Vial	2019-10-02	1248.9600	None	1	None	None	None	2019-10-01	None	1	None	Marketing pricing plan, estimated patient numbers and the acquisition price are not publicly available or in the public domain and are therefore being kept confidential.	None
Baxter Healthcare Corporation	00338006701	Doxil 50mg-25ml Vial	2019-10-02	3122.4000	None	1	None	None	None	2019-10-01	None	1	None	Marketing pricing plan, estimated patient numbers and the acquisition price are not publicly available or in the public domain and are therefore being kept confidential.	None
Baxter Healthcare Corporation	00338008001	Doxorubicin HCL, 2mg/ml x 10ml vial	2019-10-02	969.0000	None	1	None	None	None	2019-10-01	None	1	None	Marketing pricing plan, estimated patient numbers and the acquisition price are not publicly available or in the public domain and are therefore being kept confidential.	None
Baxter Healthcare Corporation	00338008601	Doxorubicin HCL, 2mg/ml x 25ml vial	2019-10-02	2422.5500	None	1	None	None	None	2019-10-01	None	1	None	Marketing pricing plan, estimated patient numbers and the acquisition price are not publicly available or in the public domain and are therefore being kept confidential.	None
Biogen	64406002001	VUMERITY™ (diroximel fumarate) 231mg Starter Bottle (106 capsules)	2019-11-22	6388.6200	Vumerity will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences for use in patients with Relapsing forms of Multiple Sclerosis. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients 2. Present and Future Benefit to Society 3. Fullfilling our commitment to Innovation 4. Evolution toward Value Based Care and 5. Affordability & Sustainability. Further information can found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf	None	344000	None	None	None	None	None	None	Vumerity is not an acquired product, nor was it granted breakthrough status or given a priority review by the FDA.	None
Biogen	64406002003	VUMERITY™ (diroximel fumarate) 231mg Maintenance Bottle (120 capsules)	2019-11-22	7232.8800	Vumerity will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences for use in patients with Relapsing forms of Multiple Sclerosis. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients 2. Present and Future Benefit to Society 3. Fullfilling our commitment to Innovation 4. Evolution toward Value Based Care and 5. Affordability & Sustainability. Further information can found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf	None	344000	None	None	None	None	None	None	Vumerity is not an acquired product, nor was it granted breakthrough status or given a priority review by the FDA.	None
Biocodex USA	68418793906	Stiripentol Oral Capsule 250 MG	2019-04-26	1500.0000	None	1	196	None	None	None	None	None	None	This drug was not acquired	None
Biocodex USA	68418794006	Stiripentol Oral Capsule 500 MG	2019-04-26	3000.0000	None	1	196	None	None	None	None	None	None	This drug was not acquired	None
Biocodex USA	68418794106	Stiripentol Oral Packet 250 MG	2019-04-26	1500.0000	None	1	196	None	None	None	None	None	None	This drug was not acquired	None
Biocodex USA	68418794206	Stiripentol Oral Packet 500 MG	2019-04-26	3000.0000	None	1	196	None	None	None	None	None	None	This drug was not acquired	None
BeiGene USA	72579001102	Brukinsa 80MG CAPSULES 120	2019-11-18	12935.0000	BeiGene considered a number of factors in deciding the price, including how BRUKINSA performed in clinical trials, the price of other therapies in the BTK inhibitor class, and the feedback we received when speaking to payers about a range of potential price points. In the U.S., BRUKINSA will be marketed to appropriate patients and physicians consistent with FDA-approved indications.	None	150	1	1	None	None	None	None	MCL indication has limited patient population. MCL prevalence was 3.0 per 100,000 persons in the UK (year 2011) and 3.6 per 100,000 persons in Belgium (year 2013).	None